Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RSMDF) EBIT (2016 - 2025)

Historic EBIT for Resmed (RSMDF) over the last 17 years, with Q4 2025 value amounting to $491.7 million.

  • Resmed's EBIT rose 1783.54% to $491.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.8 billion, marking a year-over-year increase of 1657.64%. This contributed to the annual value of $1.7 billion for FY2025, which is 2768.94% up from last year.
  • Per Resmed's latest filing, its EBIT stood at $491.7 million for Q4 2025, which was up 1783.54% from $446.5 million recorded in Q3 2025.
  • Over the past 5 years, Resmed's EBIT peaked at $491.7 million during Q4 2025, and registered a low of $223.4 million during Q1 2021.
  • Moreover, its 5-year median value for EBIT was $284.6 million (2022), whereas its average is $327.0 million.
  • Per our database at Business Quant, Resmed's EBIT crashed by 182.02% in 2023 and then surged by 5167.29% in 2024.
  • Quarter analysis of 5 years shows Resmed's EBIT stood at $248.7 million in 2021, then rose by 12.66% to $280.2 million in 2022, then fell by 1.82% to $275.1 million in 2023, then surged by 51.67% to $417.2 million in 2024, then rose by 17.84% to $491.7 million in 2025.
  • Its EBIT stands at $491.7 million for Q4 2025, versus $446.5 million for Q3 2025 and $454.5 million for Q2 2025.